Archives
-
Influenza Hemagglutinin (HA) Peptide Workflow
2026-09-30
Use the HA tag peptide for gentle competitive elution, targeted detection, and interaction mapping of HA fusion proteins. This workflow connects practical immunoprecipitation optimization with assay design for RAB31-regulated exosome studies while clearly separating established findings from recommended starting conditions.
-
Z-LEHD-FMK: Irreversible Caspase-9 Inhibitor
2026-09-29
Z-LEHD-FMK is an irreversible caspase-9 inhibitor for testing mitochondria-mediated apoptosis, caspase activity measurement, and related cancer research workflows. Product information and a graphene-melanoma study support its use as a pathway-intervention control, while also showing why inhibitor rescue should not be interpreted as proof of exclusive caspase-9 dependence.
-
Chemoproteomic Inhibitors of SLC15A4
2026-09-29
Chiu and colleagues used integrated chemical proteomics to develop functional small-molecule inhibitors of the endolysosomal transporter SLC15A4. The compounds suppressed TLR7–9 and NOD pathway activity across immune-cell models, reduced inflammatory responses in vivo, and provided translational evidence supporting SLC15A4 as a druggable target in autoimmune disease.
-
AZ 10417808 for Reproducible Cell Assays
2026-09-28
A practical, evidence-based guide to using AZ 10417808 (SKU A4416) in cell viability, proliferation, and cytotoxicity workflows. It connects ATRX-associated glioma drug-response findings with assay design, controls, interpretation, and vendor-selection decisions.
-
Pol II Degradation and Cell Death: Key Findings
2026-09-28
The preprint argues that RNA polymerase II (Pol II) degradation can activate cell death through effects not explained solely by the loss of transcription. This distinction matters for experiments that use protein depletion and transcriptional inhibition as if they were equivalent perturbations, although the citation record supplied here does not provide detailed methods or quantitative results.
-
Coumestrol Drives Ferroptosis in RA Synoviocytes
2026-09-27
A 2026 study reports that Coumestrol suppresses proliferation and inflammatory output in rheumatoid arthritis fibroblast-like synoviocytes while promoting ferroptosis. Its proposed mechanism links reduced TRIM3-mediated protein degradation to greater stability of mitochondrial PMAIP1, although the evidence is currently centered on a cell model and does not establish clinical efficacy or estrogen-receptor dependence.
-
NF449 Dissects Platelet P2 Receptor Roles in Thrombosis
2026-09-26
The study evaluated NF449 as a platelet P2X1 antagonist and tested how receptor-selective versus broader P2-receptor inhibition affects platelet activation and thrombosis. Its central finding is that a dose reported to inhibit P2X1 reduced platelet accumulation in mouse thrombosis models without a statistically significant increase in bleeding time, while a higher dose inhibited all three platelet P2 receptor subtypes.
-
Salinomycin A3785 for Reliable Cell Assays
2026-09-25
This scenario-based guide explains how to use Salinomycin (SKU A3785) in cell viability, proliferation, and apoptosis workflows without confusing metabolic changes with cell number. It covers HCC assay design, solvent and storage considerations, interpretation, and practical criteria for selecting a research-grade supplier.
-
Rucaparib Beyond BRCA: Splicing and Repair State
2026-09-25
PARP inhibitor research is moving beyond BRCA status toward a broader view of DNA repair capacity. A recent hepatocellular carcinoma study links SmD2-regulated splicing to DNA damage and PARP inhibitor sensitivity; this article examines what that finding may—and may not—mean for Rucaparib experiments.
-
From PD-L1 Stability to Reproducible Protein Biology
2026-09-24
A gastric cancer study links PRKX-dependent PD-L1 stabilization to immune exhaustion and anti-PD-1 resistance. This article translates that mechanism into practical questions for protein validation—and explains where the Influenza Hemagglutinin (HA) Peptide can support tagged-protein workflows without overstating its role in the published research.
-
Mitoxantrone HCl: Beyond Topoisomerase II
2026-09-24
Mitoxantrone HCl is best understood not only as a DNA topoisomerase II inhibitor, but also as a research probe whose emerging ERα activity invites more rigorous, mechanism-resolved experiments. This article connects DNA damage biology, assay strategy, and translational interpretation while distinguishing established findings from questions that remain open.
-
Aβ42 Peptide as a Probe of Ferroptosis in AD
2026-09-24
Amyloid β-Peptide (1-42) is more than a neurotoxicity challenge: it can help researchers distinguish membrane and ion-channel effects from ferroptosis-linked injury. This article connects Aβ42 assay design with recent evidence on the Keap1–Nrf2–GPX4 axis and explains practical controls, interpretation limits, and peptide-handling considerations.
-
Pol II Degradation and Transcription-Independent Cell Death
2026-09-23
The reference preprint shows that targeted degradation of RNA polymerase II can activate cell death through mechanisms that are not reducible to transcriptional shutdown. Its central contribution is a causal distinction between losing transcriptional output and losing the Pol II protein itself, with implications for mechanistic studies of regulated cell death, DNA damage response research, and cancer biology.
-
Tetrazolium Red in Translational Stroke Research
2026-09-22
Tetrazolium (chloride), also known as Tetrazolium Red or TTC, converts dehydrogenase activity into a spatially resolved formazan signal. This article explains how to use that biology strategically in ischemic stroke research, from mitochondrial function assay design to ex vivo lesion validation and translational decision-making.
-
Ceftazidime Workflows for Gram-Negative Research
2026-09-22
Build reproducible susceptibility, plasmid-transfer, and resistance-mapping experiments around Ceftazidime, with special relevance to Pseudomonas aeruginosa and resistant Enterobacterales. This workflow connects phenotype testing with molecular epidemiology while addressing solubility, controls, and interpretation pitfalls.